Search results
Results From The WOW.Com Content Network
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [11] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial ...
Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown. [4] [5] Use in pregnancy and breastfeeding is of unclear safety. [10] Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic ...
Side effects of statins include muscle pain, increased risk of diabetes, and abnormal blood levels of certain liver enzymes. [5] Additionally, they have rare but severe adverse effects, particularly muscle damage, and very rarely rhabdomyolysis .
Tadalafil 20-milligram side effects are often more noticeable than 10-milligram or 5-milligram side effects when it comes to acid reflux and indigestion. Adjusting your dosage might help keep the ...
For the prevention of cardiovascular disease, statins are a first-line treatment. [6] It is taken by mouth. [6] Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. [6] Serious side effects may include rhabdomyolysis, liver problems, and diabetes. [6] Use during pregnancy may harm the fetus. [6]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
[citation needed] Annual cost to the UK National Health Service (NHS) in 2018, for 5–40 mg rosuvastatin daily (of one person) was £24-40, compared to £10-20 for 20–80 mg simvastatin. [38] In 2013, it was the fourth-highest-selling drug in the United States, accounting for approximately $5.2 billion in sales. [39]
Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia.In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).